RSV STOPS HERE



AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.[1]

Learn about RSV and vaccinating with AREXVY

Not an actual patient.

Vaccination may not protect all recipients.[1]

RSV=respiratory syncytial virus.

AREXVY
(RESPIRATORY SYNCYTIAL VIRUS VACCINE, ADJUVANTED)

Important Safety Information

- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY

(continued on page 2)

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

What is RSV?

RSV is a common and contagious virus that usually causes mild, cold-like symptoms.[2,3] But sometimes, RSV infection in older adults can progress to more severe disease involving the lower respiratory tract.[2,3]

Older adults are at increased risk for severe RSV infection, **including those with certain underlying conditions.**[2]

What do you need to know about RSV?

Infections rise during fall and winter, but may vary by region in the United States[4]

Symptoms are usually mild and cold-like (but can become severe)[2]

RSV can spread through coughing or sneezing[5]

Important Safety Information (cont.)

- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting

(continued on page 3)

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

What is AREXVY?

AREXVY is the first RSV vaccine approved for the prevention of RSV-LRTD in individuals aged 60 years and older.[1]

How is AREXVY dosed and administered?[1]

Please refer to the full Prescribing Information for AREXVY for comprehensive details.

AREXVY is supplied in 2 vials that must be reconstituted prior to administration.

Administer 1 dose (0.5 mL) of AREXVY as an intramuscular injection.

Storage[1]

AREXVY should be refrigerated. DO NOT FREEZE (discard if frozen)

Store in the original package to protect vials from light

Store adjuvant suspension component vials and lyophilized antigen component vials between 2 °C and 8 °C (36 °F and 46 °F) before reconstitution

After reconstitution, administer immediately or store between 2 °C and 8 °C (36 °F to 46 °F) or at room temperature up to 25 °C (77 °F) for up to 4 hours prior to use

Protect from light. Discard reconstituted vaccine if not used within 4 hours

Important Safety Information (cont.)

- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY

(continued on page 5)

Safety and side effects[1]

The most commonly reported adverse reactions were injection site pain, fatigue, myalgia, headache, and arthralgia.

If a customer is looking for information about the safety and side effects of AREXVY, have them chat with a pharmacist.

Percentage of participants with solicited local and systemic adverse reactions within 4 days of vaccination in adults aged 60 years and older (solicited safety set with 4-day diary card)

	AREXVY %	Placebo[a] %
Local Adverse Reactions	**N=879**	**N=874**
Pain, Any[b]	60.9	9.3
Pain, Grade 3[b]	1	0
Erythema, >20 mm	7.5	0.8
Erythema, >100 mm	0.2	0
Swelling, >20 mm	5.5	0.6
Swelling, >100 mm	0.2	0
Systemic Adverse Reactions	**N=879**	**N=878**
Fatigue, Any[c]	33.6	16.1
Fatigue, Grade 3[c]	1.7	0.5
Myalgia, Any[c]	28.9	8.2
Myalgia, Grade 3[c]	1.4	0.3
Headache, Any[c]	27.2	12.6
Headache, Grade 3[c]	1.3	0
Arthralgia, Any[c]	18.1	6.4
Arthralgia, Grade 3[c]	1.3	0.6
Fever, ≥38.0 °C/100.4 °F[d]	2.0	0.3
Fever, >39.0 °C/102.2 °F[d]	0.1	0.1

STUDY DESIGN[1]:

Solicited AEs were evaluated in a subset of participants following a dose of AREXVY (n=879) or placebo (n=874). SAEs and pIMDs were monitored in all participants for 6 months following administration of AREXVY (n=12,467) or placebo (n=12,499), and AEs leading to deaths were monitored through the first analysis of Study 1.

Similar rates of SAEs (4.2% vs 4.0%), deaths (0.4% vs 0.5%), and pIMDs (0.3% vs 0.3%) were reported between AREXVY and placebo, respectively.[1]

N=exposed set for solicited safety set included all participants with at least 1 documented dose.

[a]Placebo was a saline solution.

[b]Any grade pain: Defined as any pain neither interfering with nor preventing normal everyday activities (Grade 1), painful when limb is moved and interferes with everyday activities (Grade 2), or significant pain at rest and prevents normal everyday activities (Grade 3).

[c]Any grade fatigue, myalgia, headache, arthralgia: Defined as event easily tolerated (Grade 1), interfering with normal activity (Grade 2), or preventing normal activity (Grade 3).

[d]Temperature taken by any route (oral, axillary, or tympanic).

AE=adverse event; pIMD=potential immune-mediated disease; SAE=serious adverse event.

Wondering what you can do to help?

When you see a customer aged 60 years or older, have them talk with a pharmacist about the risk of RSV, as well as vaccinating with AREXVY.[1,2]

Not an actual patient.

Coding

Use the following code when billing AREXVY:

Not actual size.

NDC: 10-dose carton 58160-848-11

For payers who require NDCs in an 11-digit format, please use: 58160-0848-11

NDC=National Drug Code.

Important Safety Information (cont.)

- The most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)

(continued on back cover)

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

RSV STOPS HERE

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.[1]

Help older adults get the information they need.

Have customers aged 60 years and older talk with a pharmacist about the risk of RSV, and vaccinating with AREXVY.[1,2]

Learn more at AREXVYhcp.com

AREXVY
(RESPIRATORY SYNCYTIAL VIRUS VACCINE, ADJUVANTED)

Vaccination may not protect all recipients.[1]

RSV=respiratory syncytial virus.

Important Safety Information (cont.)

- Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

References: 1. Prescribing Information for AREXVY. **2.** RSV in older adults and adults with chronic medical conditions. Centers for Disease Control and Prevention. Accessed November 2, 2022. https://www.cdc.gov/rsv/high-risk/older-adults.html **3.** Mesa-Frias M, Rossi C, Emond B, et al. Incidence and economic burden of respiratory syncytial virus among adults in the United States: a retrospective analysis using 2 insurance claims databases. *J Manag Care Spec Pharm*. 2022;28(7):753-765. doi:10.18553/jmcp.2022.21459 **4.** RSV Surveillance and Research. Centers for Disease Control and Prevention. Accessed April 28, 2023. https://www.cdc.gov/rsv/research/index.html **5.** RSV Transmission. Centers for Disease Control and Prevention. Accessed June 9, 2023. https://www.cdc.gov/rsv/about/transmission.html